Asistec were delighted to be an exhibitor at the 16th Annual BioProduction Congress; Europe’s leading and largest event for a comprehensive update on all aspects of large scale mammalian and microbial biological manufacturing. the event took place over two days (17th – 18th October 2017) in Dublin.

Why Dublin?

The biopharmaceutical industry has made a capital investment of approximately $8 billion in new facilities in Ireland. With most of this coming in the last 10 years, representing close to the biggest wave of investment in new biotech facilities anywhere in the world.

  • 9 of the Top 10 World’s Biopharmaceutical Companies
  • 120 Pharmaceutical Companies Operate in Ireland
  • 8th Largest Producer of Pharmaceuticals in the World
  • 33 FDA Approved Pharma & Biopharma Plants
  • €55BN in Annual Exports World’s Pharmaceutical Companies

The BioProduction Congress, bringing together over 400 of the most influential biomanufacturing folks, BioProduction 2017 provided its attendees with the latest updates across all phases of biomanufacturing, practical tips for tackling regulatory challenges head on, and a detailed overview of industry innovations in mammalian and microbial production.

Bioproduction helps you overcome the major challenges faced in the manufacturing of biological therapies: primarily monoclonal antibodies (mAbs). This year atendees got to grips with the production of novel non monoclonal antibody products, e.g. biosimilars, bispecific, antibody drug conjugates and fragments and gain an understanding of how microbial expression systems can help drive these products to market.

The event looked at the latest strategies to optimise upstream and downstream processing, minimise costs and stress on internal resources, as well as the strategies used to ensure product quality, safety and yield in line with international regulations.

Key topics included increasing product yield, optimising process, reducing timelines, ensuring quality, overcoming late stage bottlenecks and developing novel therapies coming out of the R&D department.

BioProduction 2017 looked at all aspects of large scale, commercial/ GMP manufacturing including the latest technologies, facility design, single use systems, continuous manufacturing and strategies for reducing inefficiencies during the bio manufacturing process, rather than just looking at ways to optimise the process.

Speakers at the event included: Bayer, Boehringer Ingelheim, Merck, National Institute of Bioprocessing Research & Training (NIBRT), Regeneron Pharmaceuticals, Allergan Biologics, Takeda Vaccines, Bristol Myers Squibb, PM Group, Asahi Kasai

We were joined at our booth by Jan Van Hauwermeiren of Ovizio to discuss the new feature of their iLine F microscope which is used in conjunction with Applikon Bioreactors using SMART Cell Culture Monitoring